We’re actually disrupting and changing that equation because we feel once the Spryng particles are injected into the joint, you’re going to lead to a tremendous reduction in the need of NSAIDs or any the other materials or complete elimination of it, which helps reduce the side effects onto the horse. All these other items have long-term negative effects and side effects while ours is purely neutral, and that’s how we got the veterinary device designation.
Unidentified Analyst: Years ago, there was a company that that got involved with very early turned out to be a major where they injected the hyaluronic acid into the actual cartilage that was already leaking. The problem with that is, obviously, it’s like putting air into a leaking balloon, air seeps out. I mean it could be fair to say that this is like a cartilage-type material and actually acts differently than the hyaluronic, which is actually a well-known use for equine as well as humans essential. But the point is, isn’t that a fair way of looking at it that, you’re not facing the leakage that you would normally get with the hyaluronic acid coming out of the cartilage?
John Lai: Well, yes – but also duration, duration is the key here. So once our particle goes in, that our matrix particles start forming a staffing, which actually, in essence, over probably the next month or two, the joint actually improves while if you’re using other products that are focused on symptoms. They tend to diminish after the initial injection. And each time you’re using an HA product, you’re probably diminishing the efficacy as well as the soft tissue, okay.
Unidentified Analyst: I think you’ll have the same type of luck, the same type of luck that Biomatrix had I think we could easily suppress that.
John Lai: Thank you.
John Dolan: John, would you like me to add a little bit to that?
John Lai: Sure. Go ahead.
John Dolan: Actually, you’re exactly right. When you were talking about medical devices, there are a few products in the market that have been classified as medical device, polyglycan, for example, is one and the HA products, high risk and those type of products out there that you’ve already mentioned are also considered that. John has hit it on the head though. Many of the products that are out in the market are trying to address certain symptoms that end up taking place when you end up losing or having damaged cartilage. For example, lubrication of the joint, if you put HA into a joint, you’re looking to lubricate that joint. The issue is, is you’re exactly right also, within probably 48 hours, that HA is out of the joint.
You may get some beneficial results for maybe a couple of months but then you end up losing the effectiveness of that particular medical device. Now John has hit it on the head. With our product, what we’re doing is we’re injecting a solid into the joint, a particulate that’s sponge like, that fills in all the gaps in the cartilage. So when I say it’s a particle, the nice thing about that is that it is large enough where it can’t get by the synovial membrane. So it stays inside that joint, thereby filling in all the gaps. So in other words, as John had mentioned before, you’re treating the affliction or you’re addressing the affliction by recreating that cushion between the bones.
Unidentified Analyst: Right, thank you.
Operator: We have another question.
John Lai: Go ahead.
Operator: Please unmute yourself, perfect.
Unidentified Analyst: Hi, congratulations, gentlemen, on an excellent quarter. Just had a question along the lines of from past investor presentations, you have a robust manufacturing facility with about 0.5 million unit capacity, $100 million in revenue estimated from that current production facility. Has anything changed as far that capacity capability or what has prompted the expansion into another facility at this point in time?